Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells

Cancer

Volumn 109, Issue 11, 2007, Pages 2374-2382

  Yu, Yan ^a   Zhou, Qun ^a   Hang, Yan ^a   Bu, Xuexian ^a   Jia, William ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NONE   (Canada)

Author keywords

Estrogen; Ginseng; Protopanaxadiol; Synergy; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GINSENOSIDE; LUCIFERASE; PROTEIN KINASE B BETA; PROTOPANAXADIOL; TAMOXIFEN CITRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REPORTER GENE; SCID MOUSE; TRANSCRIPTION INITIATION; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG SYNERGISM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MICE; MICE, SCID; PANAX; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; SAPOGENINS; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TRITERPENES; TUMOR CELLS, CULTURED;

EID: 34249008148     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22659     Document Type: Article

References (38)

1. Clemons M, Goss P. Estrogen and the Risk of Breast Cancer. N Engl J Med. 2001;344:276-285.
2. Key TJ, Chen J, Wang DY, Pike MC, Boreham J. Sex hormones in women in rural China and in Britain. Br J Cancer. 1990;62:631-636.
3. Hankinson S, Willett W, Manson J, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292-1299.
4. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618.
5. Borgna JL, Rochefort H. [Effects and mechanism of action of antiestrogens in breast cancer]. Sem Hop. 1984;60:703-709.
6. Gail MH, Costantino JP. Bryant J, et al. Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. J Natl Cancer Inst. 1999;91:1829-1846.
7. Salami S, Karami-Tehrani F. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem. 2003;36:247-253.
8. Fornander T, Rutqvist LE. Adjuvant tamoxifen and second cancers. Lancet 1989;1(8638):616.
9. Grese TA, Dodge JA. Selective estrogen receptor modulators (SERMs). Curr Pharm Des. 1998;4:71-92.
10. Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drugs Aging. 1999;14:323-336.
11. Jordan VC, Gottardis MM, Satyaswaroop PG. Tamoxifen-stimulated growth of human endometrial carcinoma. Ann N Y Acad Sci. 1991;622:439-446.
12. Saga Y, Ohwada M, Kohno T, Takayashiki N, Suzuki M. High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int J Gynecol Cancer. 2003;13:690-692.
13. Lee YN, Lee HY, Chung HY, et al. In vitro induction of differentiation by ginsenosides in F9 teratocarcinoma cells. Eur J Cancer. 1996;32:1420-1428.
14. Lee YN, Lee HY, Lee YM, et al. Involvement of glucocorticoid receptor in the induction of differentiation by ginsenosides in F9 teratocarcinoma cells. J Steroid Biochem Mol Biol. 1998;67:105-111.
15. Lee Y, Jin Y, Lim W, et al. A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. J Steroid Biochem Mol Biol. 2003;84:463-468.
16. Gray SL, Lackey BR, Tate PL, Riley MB, Camper ND. Mycotoxins in root extracts of American and Asian ginseng bind estrogen receptors alpha and beta. Exp Biol Med (Maywood). 2004;229:560-568.
17. Chan RY, Chen WF, Dong A, Guo D, Wong MS. Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab. 2002;87:3691-3695.
18. Duda RB, Kang SS, Archer SY, Meng S, Hodin RA. American ginseng transcriptionally activates p21 mRNA in breast cancer cell lines. J Korean Med Sci. 2001;16(suppl):S54-S60.
19. Oh M, Choi YH, Choi S, et al. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol. 1999;14:869-875.
20. Chen D, Zhao Y, Bai S, Shi Z, Zhang J. [Effect of ginsenoside Rg3 on the progression of orthotopically xenotransplanted human breast cancer in nude mice and its mechanism]. Sichuan Da Xue Xue Boo Yi Xue Ban. 2003;34:546-548.
21. Bae EA, Han MJ, Choo MK, Park SY, Kim DH. Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol Pharm Bull. 2002;25:58-63.
22. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos. 2003;31(8):1065-1071.
23. Jia W, Yan H, Bu X, Liu G, Zhao Y. Aglycone protopanaxadiol, a ginseng saponin inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells [abstract]. J Clin Oncol. 2004 ASCO Meeting Proceedings (Post-Meeting Edition). 2004;22:(Jul 15 suppl). Abstract 9663.
24. Faridi J, Wang L, Endemann G, Roth RA. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res. 2003;9:2933-2939.
25. Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat. 2004;87:167-180.
26. Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm. 2000;57:1669-1675; quiz 76-78.
27. Szucs J, Pavo I, Jurida N. [Clinical experience with raloxifene]. Orv Hetil. 2000;141:237-240.
28. Hubbard RE, Pike ACW, Brzozowski AM, et al. Structural insights into the mechanisms of agonism and antagonism in oestrogen receptor isoforms. Eur J Cancer. 2000;36(suppl 4):17-18.
29. Goldstein SR. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health. Int J Fertil Womens Med. 1999;44:221-226.
30. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994;12: 992-997.
31. Kanter-Lewensohn L, Girnita L, Girnita A, et al. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol Cell Endocrinol. 2000;165:131-137.
32. Koh J, Kubota T, Koyama T, et al. Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo. Breast Cancer. 2003;10:260-267.
33. Ramachandran C, Khatib Z, Petkarou A, et al. Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol. 2004;67:19-28.
34. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer. 2005;12:599-614.
35. deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res. 2004;10(23):8059-8067.
36. Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol. 1998;50:1155-1160.
37. Bae EA, Park SY, Kim DH. Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000;23:1481-1485.
38. Hasegawa H, Suzuki R, Nagaoka T, Tezuka Y, Kadota S, Saiki I. Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol. Biol Pharm Bull. 2002;25:861-866.